Friday, June 3, 2011

Lyxumia®, as an add-on to basal Insulin, shows significant positive phase III results

Sanofi  announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide see structure above), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patientswith type 2 diabetes without significantly increasing their risk of hypoglycemia...

More...

No comments:

Post a Comment